Caroline Dorsa
Caroline Dorsa's purchase track record
Caroline Dorsa has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/2/2025 | BIIB | $152K | +6.8% | +24.9% | +20.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Duke Energy Dividend Faces $103 Billion Test in Utility Comparisons. Recent financial news highlights Duke Energy's dividend stability, comparing it to peers like Consolidated Edison and Xcel Energy for income-oriented shareholders. A major report details a $103 billion test facing the company's dividend, underscoring the significant capital demands on its utility operations. These comparisons highlight the ongoing debate over dividend risks and growth potential within the utility sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Transaction History
| ILMN | ▲ Buy | Grant | 2,072 | $300K | 5/21/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,512 | $215K | 5/20/2026 | View on chart |
| DUK | ▲ Buy | Grant | 1,602 | $200K | 5/7/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 3,160 | $0 | 6/17/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 3,780 | $0 | 5/21/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,070 | $89K | 5/16/2025 | View on chart |
| BIIB | ▲ Buy | Open Market | 1,235 | $152K | 5/2/2025 | View on chart |
| DUK | ▲ Buy | Grant | 1,607 | $195K | 5/1/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 1,785 | $0 | 6/21/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 2,622 | $0 | 5/16/2024 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 612 | $70K | 5/15/2024 | View on chart |
| DUK | ▲ Buy | Grant | 1,699 | $175K | 5/9/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 1,580 | $0 | 6/26/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 1,532 | $0 | 5/26/2023 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 492 | $105K | 5/24/2023 | View on chart |
| DUK | ▲ Buy | Grant | 1,784 | $175K | 5/4/2023 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| NTLA | ▲ Buy | Grant | 5,197 | $0 | 6/14/2022 | View on chart |
| ILMN | ▲ Buy | Grant | 1,232 | $0 | 5/26/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 352 | $85K | 5/25/2022 | View on chart |
| DUK | ▲ Buy | Grant | 1,590 | $175K | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.